The US District Court for the District of Columbia has blocked the Aetna-Humana merger on the grounds it is anticompetitive.
The US District Court for the District of Columbia has blocked the Aetna-Humana merger. According to the decision, the efficiencies gained through the merger would not be enough “to mitigate the anticompetitive effects for consumers in the challenged markets.”
In July 2016, the Department of Justice (DOJ) filed an antitrust lawsuit to prevent both the Aetna-Humana merger and the Anthem-Cigna merger. The DOJ had been concerned that the 2 mergers, which would reduce the market from 5 big insurers to just 3, would lessen competition for individual Medicare Advantage plans and for insurance sold on the individual exchanges. After hearing arguments and reviewing the evidence, the court agrees.
Even the plan to save the merger through Aetna and Humana selling off certain Medicare Advantage assets to Molina Healthcare was not enough to appease the court.
According to the court's decision, new entrants into the market would not be sufficient to replace the competition lost by the merger. In the analysis most favorable to the defendants, there was only a 25.5% chance new entrants would make up for the lost competition, and that number could drop as low as 10%.
"So, even under the most generous of the plausible calculations the median county has a 13.3% chance of experiencing any entry, and a 25.5% chance that this new entry will be sufficient to replace the lost competition," US District Judge John D. Bates, wrote. "There is therefore a relatively small chance overall of replacing the competition lost by the proposed merger."
Aetna's spokesman, TJ Crawford, told Bloomberg that the company is reviewing the opinion and will consider appealing.
More on this story as it develops.
What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD
August 5th 2025Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.
Listen
Early Detection Strategies for Interstitial Lung Disease in Rheumatology: Janet Pope, MD, MPH
August 11th 2025Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic sclerosis, rheumatoid arthritis, and other connective tissue diseases.
Read More
Exploring the Potential of Machine Learning in Optimizing Respiratory Failure Treatment
August 9th 2025Machine learning holds promise for optimizing treatment strategies and potentially improving outcomes in respiratory failure but future research and development are necessary to fully realize its potential in clinical practice.
Read More